Proteoglycans in Cancer: The Case of Hepatocellular Carcinoma (HCC)
Below is a summarized "solid article" based on the key findings of that study. 27879.rar
Proteoglycan 4 (PRG4) has shown potential in making current chemotherapy drugs (like sorafenib) more effective by interfering with cancer cell resistance. 💡 Proteoglycans are no longer seen as just "cellular glue
Recent trials use engineered T cells to target GPC3 , effectively seeking out and destroying only the cancer cells expressing this protein. It promotes tumor growth by stimulating the Wnt
💡 Proteoglycans are no longer seen as just "cellular glue." They are dynamic regulators of the tumor microenvironment that determine how fast a tumor grows and how it responds to treatment.
A critical diagnostic marker. It is virtually absent in healthy adult livers but highly expressed in HCC. It promotes tumor growth by stimulating the Wnt and IGF signaling pathways.
The "solid" clinical takeaway is that these molecules are becoming primary targets for precision medicine: